Skip to main content
SpringerLink
Log in

Treatment of advanced breast cancer with tamoxifen: Evaluation of the dose-response relationship at two dose levels

  • Scandinavian Breast Cancer Symposium
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

In order to establish the optimal dose of tamoxifen in the treatment of advanced breast cancer in postmenopausal women, a randomized trial comparing 90 mg daily with the currently recommended dose of 30 mg daily was conducted. Sixty-eight patients were treated with the high dose and 75 patients with the low dose. The rate of response was 36 and 37% (p = 0.74), respectively. The time to response, duration of response, and the time to treatment failure were also identical at the two dose levels. Only a few side effects were observed, and they were equally distributed among the two treatment groups. It is concluded that a 30 mg daily dose of tamoxifen seems to be as effective as 90 mg.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RB, Rubin J, Frytak S: Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 304: 16–21, 1981.

    Google Scholar 

  2. Mattsson W: A phase III trial of treatment with tamoxifen versus treatment with high dose medroxyprogesteroneacetate in advanced postmenopausal breast cancer.In S Iacobelli and A Di Marco (eds). Role of Medroxyprogesterone in Endocrine-Related Tumours. Progress in Cancer Research and Therapy, Vol 15. Raven Press, New York, 1980, pp 65–71.

    Google Scholar 

  3. Westerberg H: Tamoxifen and fluoxymesterone in advanced breast cancer: a controlled clinical trial. Cancer Treat Rep 64: 117–121, 1980.

    Google Scholar 

  4. Smith IE, Harris AL, Morgan M, Ford HT, Gazet J-C, Harmer CL, White H, Parsons CA, Villardo A, Walsh G, McKinna JA: Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J 283: 1432–1434, 1981.

    Google Scholar 

  5. Patterson JS: ‘Nolvadex’ (tamoxifen) as an anti-cancer agent in humans.In RL Sutherland and VC Jordan (eds). Non-steroidal Antiestrogens. Molecular Pharmacology and Antitumour Activity. Academic Press Australia, 1981, pp 453–472.

  6. Ward HWC: Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br Med J 1: 13–14, 1973.

    Google Scholar 

  7. Fabian C, Sternson L, El-Serafi M, Cain L, Hearne E: Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer 48: 876–882, 1981.

    Google Scholar 

  8. Manni A, Arafah BM: Tamoxifen-induced remission in breast cancer by escalating the dose to 40 mg daily after progression on 20 mg daily: a case report and review of the literature. Cancer 48: 873–875, 1981.

    Google Scholar 

  9. Stewart JF, Minton MJ, Rubens RD: Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily. Cancer Treat Rep 66: 1445–1446, 1982.

    Google Scholar 

  10. Westerberg H, Nordenskjöld B, Schryver A, Notter G: Anti-oestrogen therapy of advanced mammary carcinoma. Acta Radiol Ther Phys Biol 15: 513–518, 1976.

    Google Scholar 

  11. Hayward JL, Carbone PP, Heuson J-C, Komaoka S, Segalof FA, Rubens RD: Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13: 89–94, 1977.

    Google Scholar 

  12. EORTC Breast Co-operative Group: Revision of standards for the assessment of hormone receptors in human breast cancer: report of the second EORTC workshop. Eur J Cancer 16: 1513–1515, 1980.

    Google Scholar 

  13. Wulff HR: Confidence limits in evaluating controlled therapeutic trials. Lancet 2: 969, 1973.

    Google Scholar 

  14. Lerner HJ, Band PR, Israel L, Leung BS: Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. Cancer Treat Rep 60: 1431–1435, 1976.

    Google Scholar 

  15. Tormey DC, Lippman MF, Edwards BE, Cassidy J: Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer (in preparation).

  16. Furr BJ, Patterson JS, Richardson DN, Slater SR, Wakeling AE: Tamoxifen.In ME Goldberg (ed). Pharmacological and Biochemical Properties of Drug Substances, Vol 2. A.P.A., Washington, 1981, pp 355–399.

    Google Scholar 

  17. Katzenellenbogen BS: Basic mechanisms of antiestrogen action.In WL McGuire (ed). Hormones, Receptors, and Breast Cancer. Progress in Cancer Research and Therapy, Vol 10. Raven Press, New York, 1978, pp 135–157.

    Google Scholar 

  18. Sutherland RL, Murphy LC: The binding of tamoxifen to human mammary carcinoma cytosol. Eur J Cancer 46: 1141–1148, 1980.

    Google Scholar 

  19. Carter AC, Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR: Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the co-operative breast cancer group. JAMA 237: 2079–2085, 1977.

    Google Scholar 

  20. Løber J, Rose C, Salimtschik M, Mouridsen HT: Treatment of advanced breast cancer with progestins — a review. Acta Obstet Gynecol Scand, Suppl 101: 39–46, 1981.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology A, The Finsen Institute, Strandboulevarden 49, 2100 DK, Copenhagen Ø, Denmark

    Carsten Rose M.D., Karen Theilade M.D., Else Boesen M.D., Marianne Salimtschik M.D. & Henning T. Mouridsen M.D.

  2. Medical Department C, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 DK, Copenhagen NV, Denmark

    Per Dombernowsky M.D.

  3. Department of Oncology, Herlev Amtssygehus, Herlev Ringvej, 2730 DK, Copenhagen Herlev, Denmark

    Per Dombernowsky M.D., Niels Brünner M.D. & Mogens Kjær M.D.

  4. The Fibiger Laboratory, Ndr. Frihavnsgade 70, 2100 DK, Copenhagen Ø, Denmark

    Carsten Rose M.D.

Authors
  1. Carsten Rose M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen Theilade M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Else Boesen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marianne Salimtschik M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Per Dombernowsky M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Niels Brünner M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mogens Kjær M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Henning T. Mouridsen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rose, C., Theilade, K., Boesen, E. et al. Treatment of advanced breast cancer with tamoxifen: Evaluation of the dose-response relationship at two dose levels. Breast Cancer Res Tr 2, 395–400 (1982). https://doi.org/10.1007/BF01805882

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01805882

Keywords

Search

Navigation